Therapeutic potential of TAS-115 in 3D breast cancer models

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. TAS-115, a multi-receptor tyrosine kinase inhibitor, has not previously been evaluated in TNBC. Here, we investigated its therapeutic effects alone and in combination with doxorubicin (DOXO), using three-dimensional heterotypic spheroid models, including free-standing, bioprinted static, and perfused systems. TAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling. Combined treatment with DOXO further amplified these effects. In perfused bioprinted models, TAS-115 markedly inhibited tumor cell migration, highlighting its potential to limit metastatic behavior. These findings identify TAS-115 as a promising therapeutic strategy for TNBC, either as a monotherapy or in combination with chemotherapy.

Authors

Institutions

Publication Details

Journal
Biofabrication
Published
2025-11-25
DOI
https://doi.org/10.1088/1758-5090/ae2400
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Therapeutic potential of TAS-115 in 3D breast cancer models

Sendegül Yıldırım, Nazmiye Celik, Momoka Nagamine, Amanda Blanque Becceneri et al.
Biofabrication
Cancer Cells and Metastasis
article

Therapeutic potential of TAS-115 in 3D breast cancer models

Sendegül Yıldırım, Nazmiye Celik, Momoka Nagamine, Amanda Blanque Becceneri, Gamze Tanrιöver, Todd M. Umstead, Myoung‐Hwan Kim, Ibrahim Tarik Ozbolat, İlayda Namlı, Zissis C. Chroneos
article en

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. TAS-115, a multi-receptor tyrosine kinase inhibitor, has not previously been evaluated in TNBC. Here, we investigated its therapeutic effects alone and in combination with doxorubicin (DOXO), using three-dimensional heterotypic spheroid models, including free-standing, bioprinted static, and perfused systems. TAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling. Combined treatment with DOXO further amplified these effects. In perfused bioprinted models, TAS-115 markedly inhibited tumor cell migration, highlighting its potential to limit metastatic behavior. These findings identify TAS-115 as a promising therapeutic strategy for TNBC, either as a monotherapy or in combination with chemotherapy.

BiofabricationVol. 18(1)
University of Iowa (US), Pennsylvania State University (US), Johns Hopkins University (US), Universidade de São Paulo (BR), Akdeniz University (TR), Engineering Arts (United States) (US), Millennium Engineering and Integration (United States) (US), Cukurova University (TR), Penn State Milton S. Hershey Medical Center (US)
Openalex Percentile: Top 50%
Cancer Cells and Metastasis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.